Register for our free email digests:
Amgen Astellas BioPharma KK
Division of Amgen Inc.
Latest From Archemix Corp.
Californian biotech company True North Therapeutics has appointed Dr James Gilbert chief medical officer, and raised $22m in its series A financing round to enable it to move its lead candidate into the clinic. True North is developing novel therapies that selectively inhibit the complement system to treat rare diseases.
Ophthotech raised $175 million, mostly in the form of royalty financing from Novo A/S, to fund a 1,900-patient Phase III clinical trial for its anti-platelet-derived growth factor (anti-PDGF) aptamer Fovista in combination with an anti-VEGF therapy for the treatment of wet age-related macular degeneration (AMD).
Deerfield Management, the $3.5 billion health care hedge fund, is aggressively expanding its investments in private life sciences companies. As many VCs continue to struggle raising new funds Deerfield hopes its shift, combined with a flexible, research-driven approach to investing and a new involvement in the civic and academic activities shaping the sector, will secure its position as a top health care financier.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.